Share Information:
ROS Therapeutics ApS is a privately held company, operating under the CVR number 39507501
Stock Information:
Number of shares: 81,565
Nominal value per share: DKK 1
Share capital: DKK 81,565
Shareholders holding more than 5% of the shares:
ROS Therapeutics Holding ApS
INNOVATIONS A/S
Rasmus Wilhelmsen
Principal Law Firm:
Bach Advokater / Ricki Boye
Key dates:
Founded: 23rd of April, 2018
Most recent capital increase: 12th of July, 2018
Most recent Annual General Meeting: Not applicable
Financial Calendar year-end: 31 December
NEWS
Health Europa Quarterly (issue 07) highlights the advantages and disadvantages of the currently recommended first-line treatment for rheumatoid arthritis and reflects on recent research into a possible alternative: A new targeted-MTX treatment underway for rheumatoid arthritis
A New targeted MTX underway for RA
2018-11-11
ROS Therapeutics today announces the successful closing of a DKK 10.1 mill. seed financing round with participation of founders, advisors, business angels and other private investors.
ROS Therapeutics™ raises DKK 10 million in seed financing round
2018-07-13
ROS Therapeutics™ signs patent license agreement with the Technical University of Denmark (DTU) regarding molecules for the treatment of inflammatory diseases and cancer
ROS Therapeutics™ signs patent license agreement
2018-07-03
